NASDAQ:BDSX

Biodesix (BDSX) Stock Price, News & Analysis

Biodesix logo
$8.40 -0.48 (-5.41%)
Closing price 04:00 PM Eastern
Extended Trading
$8.38 -0.02 (-0.24%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Biodesix Stock (NASDAQ:BDSX)

Advanced

Key Stats

Today's Range
$8.36
▼
$9.04
50-Day Range
$8.53
▼
$30.42
52-Week Range
$5.26
▼
$31.97
Volume
168,630 shs
Average Volume
484,693 shs
Market Capitalization
$93.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.20
Consensus Rating
Moderate Buy

Company Overview

Biodesix, Inc. is a molecular diagnostics company focused on blood-based testing and data-driven tools for lung disease, particularly lung cancer. The company develops and provides diagnostic tests intended to help clinicians assess lung nodules and inform treatment decisions.

Its products include the Nodify Lung suite, which is designed to support assessment of lung nodules, and VeriStrat, a blood-based test that helps inform treatment decisions for patients with non-small cell lung cancer. Biodesix also offers laboratory and diagnostic services to pharmaceutical and biotechnology companies.

Based in Colorado, Biodesix primarily serves clinicians and patients in the United States through its diagnostic testing services. Its work combines molecular analysis with clinical data to support decision-making across lung cancer care.

AI Generated. May Contain Errors.

Biodesix Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
80th Percentile Overall Score

BDSX MarketRank™: 
4.01108557523 of 5 stars

Biodesix scored higher than 80% of companies evaluated by MarketBeat, and ranked 169th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biodesix has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Biodesix has a consensus price target of $34.20, representing about 307.1% upside from its current price of $8.40.

  • Amount of Analyst Coverage

    Biodesix has only been the subject of 4 research reports in the past 90 days.

  • Read more about Biodesix's stock forecast and price target.
  • Earnings Growth

    Earnings for Biodesix are expected to grow in the coming year, from ($2.95) to ($1.94) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biodesix is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biodesix is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Biodesix has a P/B Ratio of 10.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.59% of the float of Biodesix has been sold short.
  • Short Interest Ratio / Days to Cover

    Biodesix has a short interest ratio ("days to cover") of 2.46, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biodesix has recently increased by 0.25%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Biodesix does not currently pay a dividend.

  • Dividend Growth

    Biodesix does not have a long track record of dividend growth.

  • News Sentiment

    Biodesix has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Biodesix this week, compared to 4 articles on an average week.
  • Search Interest

    2 people have searched for BDSX on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Biodesix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $1,002,000.00 in company stock, which represents 1.0756% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Biodesix insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,002,000.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    23.20% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    20.96% of the stock of Biodesix is held by institutions.

  • Read more about Biodesix's insider trading history.
Receive BDSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BDSX Stock News Headlines

Biodesix Earnings Call Shows Growth Amid Execution Challenges
Beyond NVDA: The World’s Next #1 Company?
This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.tc pixel
Insider Buying: Biodesix (NASDAQ:BDSX) Director Buys $1,002,000.00 in Stock
See More Headlines

BDSX Stock Analysis - Frequently Asked Questions

Biodesix's stock was trading at $6.80 at the start of the year. Since then, BDSX stock has increased by 23.5% and is now trading at $8.40.

Biodesix, Inc. (NASDAQ:BDSX) posted its quarterly earnings data on Thursday, November, 5th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by $0.00. The company had revenue of $24.04 million for the quarter, compared to the consensus estimate of $27.48 million. Biodesix had a negative net margin of 25.74% and a negative trailing twelve-month return on equity of 442.34%.
Read the conference call transcript
.

Biodesix shares reverse split before market open on Monday, September 15th 2025.The 1-20 reverse split was announced on Thursday, September 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Biodesix (BDSX) raised $72 million in an IPO on Wednesday, October 28th 2020. The company issued 4,000,000 shares at $17.00-$19.00 per share. Morgan Stanley and William Blair served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Top institutional shareholders of Biodesix include AIGH Capital Management LLC (6.50%), Soleus Capital Management L.P. (6.02%), Aberdeen Group plc (2.73%) and Marshall Wace LLP (1.67%). Insiders that own company stock include Jack W Schuler, Matthew Strobeck, John Patience, Scott Hutton, Robin Harper Cowie, Gary Anthony Pestano, Kieran O'kane and Chris Vazquez.
View institutional ownership trends
.

Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biodesix investors own include Palantir Technologies (PLTR), Energy Transfer (ET), Intel (INTC), Micron Technology (MU), NVIDIA (NVDA), SEALSQ (LAES) and Aldeyra Therapeutics (ALDX).

Company Calendar

Last Earnings
11/05/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Services
Current Symbol
NASDAQ:BDSX
CIK
1439725
Fax
N/A
Employees
334
Year Founded
2005

Price Target and Rating

High Price Target
$40.00
Low Price Target
$30.00
Potential Upside/Downside
+307.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.76)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$35.26 million
Net Margins
-25.74%
Pretax Margin
-25.74%
Return on Equity
-442.34%
Return on Assets
-29.16%

Debt

Debt-to-Equity Ratio
5.43
Current Ratio
2.96
Quick Ratio
2.96

Sales & Book Value

Annual Sales
$88.50 million
Price / Sales
1.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.78 per share
Price / Book
10.77

Miscellaneous

Outstanding Shares
11,090,000
Free Float
8,516,000
Market Cap
$93.16 million
Optionable
No Data
Beta
0.65

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:BDSX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners